Standard diagnostic and therapeutic process of HCV chronic infection

Česká verzia

Authors: P. Urbánek; P. Husa; J. Galský; J. Šperl ; V. Hejda; P. Kümpel; V. Němeček; S. Plíšek; M. Volfová
Authors place of work: Pracovní skupina pro virové hepatitidy České hepatologické společnosti ČLS JEP, Pracovní skupina pro virové hepatitidy Společnosti infekčního lékařství ČLS JEP
Published in the journal: Gastroent Hepatol 2012; 66(3): 214-229
Category: Hepatology: Best Practises

Zdroje

1. European Association for the Study of the Liver: EASL Clinical Practice Guidelines: Management of hepatitis C virus infection. J Hepatol 2011; 55(2): 245–264.

2. Ghany MG, Nelson DR, Strader DB et al. An Update on Treatment of Genotype 1 Chronic Hepatitis C Virus Infection: 2011 Practice Guideline by the American Association for the Study of Liver Diseases. Hepatology 2011; 54(4): 1433–1444.

3. Poordad F, McCone J Jr., Bacon BR et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364(13): 1195–1206.

4. Jacobson IM, McHutchison JG, Dusheiko G et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364(25): 2405–2416.

5. Sherman KE, Flamm SL, Afdhal NH et al. Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med 2011; 365(11): 1014–1024.

6. Bacon BR, Gordon SC, Lawitz E et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011; 364(13): 1207–1217.

7. Zeuzem S, Andreone P, Pol S et al. Telaprevir for retreatment of HCV infection. N Engl J Med 2011; 364(25): 2417–2428.

8. Strader DB, Wright T, Thomas DL et al. Diagnosis, Management, and treatment of hepatitis C. AASLD Practice Guideline. Hepatology 2004; 39(4): 1147–1171.

9. Manns MP, McHutchison JG, Gordon SC et al. PEG-interferon alfa-2b in combination with ribavirin compared to interferon alfa 2b plus ribavirin for initial treatment of chronic hepatitis C. Lancet 2001; 358(9286): 958–965.

10. Fried MW, Shiffman ML, Reddy KR et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975–982.

11. Hadziyannis SJ, Sette H, Morgan TR et al. Peginterferon alfa-2a (40 kilodaltons) and ribavirin combination therapy in chronic hepatitis C: randomized study of the effect of treatment duration and ribavirin dose. Ann Intern Med 2004; 140(5): 346–355.

12. Zeuzem S, Buti M, Ferenci P et al. Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. J Hepatol 2006; 44(1): 97–103.

13. Zeuzem S, Pawlotsky J-M, Lukasiewicz E et al. International, multicenter, randomized, controlled study comparing dynamically individualized versus standard treatment in patients with chronic hepatitis C. J Hepatol 2005; 43(2): 250–257.

14. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. Centers for Disease Control and Prevention. MMWR Recomm Rep 1998; 47(RR-19): 1–39.

15. Hu J, Doucette K, Hartling L et al. Treatment of Hepatitis C in Children: A Systematic Review. PLoS One 2010; 5(7): e11542.

16. Schwarz KB et al. Peginterferon with or without ribavirin for chronic hepatitis C in children and adolescents: final results of the PEDS-C trial. Hepatology 2008; 48 (4 Suppl): 418A.

17. Wirth S et al. Children with HCV infection show high sustained virologic response on peginterferon alfa-2b plus ribavirin treatment. Hepatology 2008; 48 (4 Suppl): 392A.

18. Wirth S, Ribes-Kominckx C, Calzado MA et al. High sustained virologic response rates in children with chronic hepatitis C receiving peginterferon alfa-2b plus ribavirin. J Hepatol 2010; 52(4): 501–507.